MONOPOLY: predicting clinical benefit of dupilumab in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP)

MONOPOLY: predicting clinical benefit of dupilumab in adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP) - Dupilumab in patients with CRSwNP

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON54163

Enrollment

130

Registered

2020-12-16

Start date

2021-01-14

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic rhinosinusitis with nasal polyps

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: bilateral CRSwNP (EPOS2020 criteria) >= 18 years indication for biological (EPOS2020 criteria) and starting treatment with dupilumab (for EPOS 2020 criteria see reference in METC protocol)

Exclusion criteria

Exclusion criteria: • age

Design outcomes

Primary

Measure	Time frame
Histochemical and single cell suspension flow cytometry analysis	—

Secondary

Measure	Time frame
does not apply	—

Countries

Netherlands

Outcome results